Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

  1. Rugo, H.S.
  2. André, F.
  3. Yamashita, T.
  4. Cerda, H.
  5. Toledano, I.
  6. Stemmer, S.M.
  7. Jurado, J.C.
  8. Juric, D.
  9. Mayer, I.
  10. Ciruelos, E.M.
  11. Iwata, H.
  12. Conte, P.
  13. Campone, M.
  14. Wilke, C.
  15. Mills, D.
  16. Lteif, A.
  17. Miller, M.
  18. Gaudenzi, F.
  19. Loibl, S.
Revista:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Any de publicació: 2020

Volum: 31

Número: 8

Pàgines: 1001-1010

Tipus: Article

DOI: 10.1016/J.ANNONC.2020.05.001 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus